Leading Skin Cancer Research from the Dermatology Clinic

Rubeta Matin is a Consultant Dermatologist with an interest in Cutaneous Oncology based at Oxford University Hospitals NHS Foundation Trust. Her research career stems from a MRC Clinical Training Fellowship investigating treatment resistance of melanoma (2006-2009), which led to a PhD in Molecular Mechanisms in Melanoma. She is Dermatology Research Lead for Skin Cancer and runs an active clinical research programme, currently Chief Investigator for four clinical trials and Principal Investigator for five trials.

 “As a clinician I work at the interface with patients ensuring that the research that I do is always focused on improving patient outcomes.” 

Early skin cancer diagnosis and prevention

Rubeta is a core member of the Cochrane Skin Cancer Diagnostic Test Accuracy Group co-authoring a suite of systematic reviews evaluating diagnosis and staging of skin cancers. She also leads an international commercial collaboration testing a novel digital dermatoscope in secondary care aimed to enhance diagnostic accuracy.

Skin toxicity associated with targeted treatments  / immunotherapy in metastatic melanoma. 

Rubeta is collaborating with the Medical Oncology Melanoma Team to investigate the clinicopathological diversity of skin toxicities and T-cell responses in the skin of melanoma patients treated with immune-checkpoint blockers. Skin reactions are the most frequent and earliest side effects of immune checkpoint inhibitors which are used to treat metastatic melanoma and increasingly used in other cancers. The clinical and molecular features of skin toxicity are poorly characterised and many individuals are not managed by dermatologists with expertise in these novel toxicities.

Patient Reported Outcomes 

As leader of a workstream evaluating Patient Reported Outcome (PRO) in skin cancers in collaboration with NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC), Rubeta’s research seeks to improve care by integrating patient perspectives. She has collaborated with the CLAHRC patient experiences and patient reported outcomes theme evaluating feasibility of using the Skin Cancer Quality of Life Impact Tool in skin cancer screening clinics.

Collaborators in Oxford include Mark Middleton, Benjamin Fairfax and Miranda Payne (Medical Oncology), Crispin Jenkinson and Ray Fitzpatrick (Patient Reported Outcomes), and Graham Collins (Haematology). National collaborators are Catherine Harwood (Barts Health Trust) and Charlotte Proby (Dundee).

Rubeta is funded by NIHR Research for Patient Benefit Grant, Skin Cancer Research Fund, UK Dermatology Clinical Trials Network Themed Call Research Fund, and Oxfordshire Health Services Research Committee.

Find out more about our research below

Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens

University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.

Two clinical academic research partnerships awarded to Oxford researchers

Congratulations to Dr Karthik Ramasamy & Dr John Jacob on their CARP awards from the Medical Research Council. Find more about their work that is being funded

Groundbreaking FOCUS4 clinical trials report their findings at ASCO

Principal Investigator Tim Maughan talks about the forward-thinking approach of the FOCUS4 cancer clinical trials and how they have helped shape the UK's fight against COVID-19

Cancer immunologist Lieping Chen joins Ludwig Oxford as a Visiting Professor

Oxford is delighted to welcome this acclaimed scientist to the Branch and the Ludwig Oxford community.

New prostate cancer risk tool

A new calculator has been developed by Professors Julia Hippisley-Cox and Carol Coupland to help GPs prioritise patients at high risk of prostate cancer.

Understanding mutation progression to detect ovarian cancer earlier

Nina Wietek from the Ahmed lab is investigating fallopian tube tissue to see what we can understand about precancerous mutations in the tissue from which ovarian cancers develops.

New study investigates how growth factors in our gut could initiate cancer

Dr Francesco Boccellato is investigating the mechanisms of tissue regulation in the healthy stomach and in a pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing

Using Herpesvirus to fight cancer

The Seymour lab at the Department of Oncology, University of Oxford, has published a new paper investigating the use of oncolytic herpes virus-1 as a vector to augment immunotherapy in cancer

Oxford success at the early detection sandpit on pancreatic cancer

Professor Eric O’Neill and Dr Pui San Tan receive funding as part of teams applying novel approaches for the early detection of pancreatic cancer.